Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 4/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.38 |
| ▸ | EBP | Q15125 | 1/20 | 0.38 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | G6PD | P11413 | 2/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4938592 | 1.00 | BCHE (0.42) | BCHEACHESERPINA6EBPDHCR7 | |
| SCHEMBL4939251 | 0.82 | ESR1 (0.40) | SERPINA6KMT2ALMNACYP3A4 | |
| SCHEMBL4938544 | 0.82 | ESR1 (0.40) | SERPINA6KMT2ALMNACYP3A4 | |
| SCHEMBL4945380 | 0.82 | ESR1 (0.40) | SERPINA6KMT2ALMNACYP3A4 | |
| SCHEMBL4945781 | 0.82 | ESR1 (0.40) | SERPINA6KMT2ALMNACYP3A4 | |
| SCHEMBL4938549 | 0.82 | ESR1 (0.40) | SERPINA6KMT2ALMNACYP3A4 | |
| SCHEMBL5088077 | 0.81 | HSD11B1 (0.39) | BCHESERPINA6MEN1KMT2AMAPK1 | |
| SCHEMBL4942231 | 0.81 | HSD11B1 (0.39) | BCHESERPINA6MEN1KMT2AMAPK1 | |
| SCHEMBL4936668 | 0.81 | HSD11B1 (0.39) | BCHESERPINA6MEN1KMT2AMAPK1 | |
| SCHEMBL4943571 | 0.81 | HSD11B1 (0.39) | BCHESERPINA6MEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130164780-A1 | Drug Identification Method | BIOVIE INC. | 2013-06-27 | — | — | US | disclosed |
| US-8354396-B2 | Identifying compounds that can treat autoimmune conditions; ulcerative colitis, inflammatory bowel disease, Crohn's disease, psoriasis, actinic keratosis, arthritis, multiple sclerosis, optic neuritis | Harbor Therapeutics, Inc. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8217025-B2 | Utilizing such as 4-fluoro-17-ethynylandrost-5-ene-3-,7-,17-triol; pulmonary conditions, hyperglycemia, type 2 diabetes, insulin resistance | Harbor Therapeutics, Inc. (US) | 2012-07-10 | — | — | US | disclosed |
| US-20080221074-A1 | Drug Screen and Treatment Method | BIOVIE INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080153792-A1 | Drug Identification and Treatment Method | BIOVIE INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153797-A1 | Drug Identification and Treatment Method | BIOVIE INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080146532-A1 | Utilizing such as 4-fluoro-17-ethynylandrost-5-ene-3-,7-,17-triol; pulmonary conditions, hyperglycemia, type 2 diabetes, insulin resistance | BIOVIE INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153792-A1 | Drug Identification and Treatment Method | PTGER4, PTGER1, IL17A | BCHE 2801/4885ACHE 1003/4885SERPINA6 763/4885 |
| US-20080146532-A1 | Utilizing such as 4-fluoro-17-ethynylandrost-5-ene-3-,7-,17-triol; pulmonary conditions, hyperglycemia, type 2 diabetes, insulin resistance | HSD17B1, HSD17B11, HSD3B2 | BCHE 2638/4885ACHE 3452/4885SERPINA6 472/4885 |
| US-20080221074-A1 | Drug Screen and Treatment Method | HSD3B2, HSD17B2, HSD3B1 | BCHE 1218/4885ACHE 1741/4885SERPINA6 513/4885 |
| US-20080153797-A1 | Drug Identification and Treatment Method | PTGER4, PTGER1, IL17A | BCHE 2830/4885ACHE 1013/4885SERPINA6 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.